You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Results of regression analysis of processeda quarterly health costs in first year after baseline (N = 5463)

From: Telemedical monitoring of patients with chronic heart failure has a positive effect on total health costs

  Reference Estimate [in €] CI 95% P-value
2.5% 97.5%
Study group Control group −276.04 − 573.18 21.10 0.0686
Residential area (Berlin vs. rural) Rural 180.81 −49.03 410.65 0.1231
Interaction: Group x Residential area 257.77 −131.35 646.90 0.1941
Age group
 46–50 years 41–45 years 878.30 − 652.97 2409.58 0.2609
 51–55 years 41–45 years 669.75 − 749.92 2089.43 0.3551
 56–60 years 41–45 years 641.50 −743.15 2026.14 0.3638
 61–65 years 41–45 years 448.94 − 905.54 1803.43 0.5159
 66–70 years 41–45 years 828.90 −502.34 2160.14 0.2223
 71–75 years 41–45 years 1117.78 − 210.13 2445.69 0.0990
 76–80 years 41–45 years 1160.55 − 167.31 2488.41 0.0867
 81–85 years 41–45 years 973.17 − 359.70 2306.04 0.1524
 86–90 years 41–45 years 876.95 − 471.87 2225.77 0.2025
 91–95 years 41–45 years 1168.45 − 340.20 2677.11 0.1290
Sex Male −73.85 −245.19 97.49 0.3982
NYHA class
NYHA II NYHA I 18.38 − 793.15 829.91 0.9646
NYHA III NYHA I 210.53 −600.60 1021.65 0.6109
NYHA IV NYHA I 398.18 −419.09 1215.45 0.3396
 Hospitalizations related to CHF (continuous) 52.03 −51.72 155.79 0.3256
 Baseline health costs (continuous) 0.37 0.34 0.40 < 0.0001***
Intake of medication related to CHF (yes / no by groups of agents)
 Angiotensin-converting enzyme no − 139.92 −313.52 33.69 0.1142
 Beta-blocker no −279.06 − 450.13 − 107.98 0.0014**
 Renin-inhibitors no −75.07 − 734.15 584.01 0.8233
 Cardiac glycosides no 147.81 −81.40 377.01 0.2062
 Diuretics no 394.65 214.89 574.40 < 0.0001***
 AT1 receptor blocker no −25.55 − 247.64 196.54 0.8216
Mental and behavioral disorders (yes / no by blocks of ICD-10 Chapter V)
 F00 – F09 (Organic, including symptomatic, mental disorders) no 465.72 173.79 757.65 0.0018**
 F10 – F19 (Mental and behavioral disorders due to psychoactive substance use) no 39.64 − 257.67 336.94 0.7938
 F20 – F29 (Schizophrenia, schizotypal and delusional disorders) no −34.52 − 936.45 867.41 0.9402
 F30 – F39 (Mood [affective] disorders) no 109.85 −120.77 340.48 0.3504
 F40 – F49 (Neurotic, stress-related and somatoform disorders) no 51.25 − 188.92 291.42 0.6757
 F50 – F59 (Behavioral syndromes associated with physiological disturbances and physical factors) no 343.92 − 130.81 818.64 0.1556
 F60 – F69 (Disorders of adult personality and behavior) no −120.35 − 859.94 619.25 0.7497
 F70 – F79 (Mental retardation) no 321.91 −921.90 1565.71 0.6119
 F80 – F89 (Disorders of psychological development) no
 F90 – F98 (Behavioral and emotional disorders with onset usually occurring in childhood and adolescence) no 612.00 − 991.08 2215.09 0.4542
 F99 – F99 (Unspecified mental disorders) no 490.90 − 1333.73 2315.52 0.5979
Intercept 249.86 − 1318.15 1817.88 0.7548
  1. aHealth costs after performing the excluding-and-capping algorithm, Significance codes: ***p < 0.001, **p < 0.01, *p < 0.05